Anterior Uveitis Treatment Market Size, Share, Analysis 2031

Anterior Uveitis Treatment Market Size, Share, Analysis 2031

Segments - Global Anterior Uveitis Treatment Market by Treatments (Corticosteroids, Cycloplegic Agents, Anti-TNF Agents, and Immunosuppressants), Distribution Channels (Hospitals Pharmacies, Retail Pharmacies, and Online Pharmacies), and Regions (Asia Pacific, North America, Europe, Latin America, and Middle East & Africa) Forecast, 2023 - 2031

https://growthmarketreports.com/raksha
Author : Raksha Sharma
https://growthmarketreports.com/Vineet
Fact-checked by : Vineet Pandey
https://growthmarketreports.com/Vishal
Editor : Vishal Golekar

Upcoming | Report ID :HC-908 | 4.3 Rating | 62 Reviews | 135 Pages | Format : PDF Excel PPT

Report Description


Global Anterior Uveitis Treatment Market Outlook 2031:

The Global Anterior Uveitis Treatment Market size was valued at USD 700 Million in 2022 and is projected to reach USD 1.25 Billion by 2031, expanding at a CAGR of 6.7% during the forecast period 2023 - 2031The growth of the market is attributed to Increasing prevalence of anterior uveitis across the globe.

Uveitis is a group of inflammatory diseases that destroys eye tissues and causes uvea (middle layer of eye) swelling. These diseases can sometimes lead to severe vision loss. The various types of uveitis are posterior uveitis, anterior uveitis, panuveitis uveitis, and intermediate uveitis. Some diseases such as AIDS, multiple sclerosis, rheumatoid arthritis, tuberculosis, and ulcerative colitis increases the risk of uveitis.

Anterior uveitis affects the front, colored part of the eye, the iris and hence, it is also known as iritis. It is commonly seen in young and middle-aged people. The common symptoms of anterior uveitis include pain, photophobia, redness, decreased vision, and lacrimation. These symptoms if not treated can result in permanent blindness.

Anterior Uveitis Treatment Market Outlook

  • Favorable government regulations and growing geriatric population is estimated to contribute to the market growth during the forecast period.
  • Ongoing developments in the applications of products and treatment modalities are expected to provide long term opportunity for the market growth.
  • Factors such as lack of knowledge about eye-related diseases, steep prices of medications, unavailability of health insurance in some developing countries, and side effects of medication including watery eyes and irritation are expected to hinder the market growth.

Scope of the Anterior Uveitis Treatment Market report:

The report on anterior uveitis treatment market includes an assessment of the market, size, share, trends, segments, and regional markets. Overview and dynamics have been included in the report.

Attributes

Details

Base Year

2022

Historic Data

2016–2021

Forecast Period

2023–2031

Regional Scope

Asia Pacific, North America, Europe, Latin America, and Middle East & Africa

Report Coverage

Market scope, analysis, share, competitive analysis, growth facts, restraints, opportunities and revenue forecast

Anterior Uveitis Treatment Market Segment Insights:

Several advantages of corticosteroids over other treatments are driving the segmental growth

Based on treatment types, the global anterior uveitis treatment market can be bifurcated into corticosteroids, cycloplegic agents, anti-tnf agents, and immunosuppressants. The corticosteroids segment held a significant market share, as they are first line therapies for anterior uveitis. Corticosteroids are inexpensive, potent, and act fast.

Moreover, they may be administered systematically (oral, intramuscular or intravenous routes), topically, or through periocular injections. Furthermore, corticosteroids are mostly preferred over biologics. Hence, the segment is expected to expand at a substantial CAGR during the forecast period.

Anterior Uveitis Treatment Market Treatment Type

Online pharmacies segment is expected to register higher CAGR during the forecast period

On the basis of distribution channels, the market can be segmented into hospital pharmacies, retail pharmacies, and online pharmacies. Online pharmacies segment is expected to expand at a significant CAGR during the forecast period.

The growth of the segment is attributed to the increasing popularity of online pharmacies owing to the advantages such as convenience, time saving, low price, and insights on the usage of drugs. Moreover, increasing number of Internet users and higher dependency on online goods are expected to boost the market growth during the forecast period.

Anterior Uveitis Treatment Market Distribution Channel

North America is expected to account for a significant share of the global market

Based on regions, the global anterior uveitis treatment market is fragmented into North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. North America held the highest market share and is projected to expand at a moderate CAGR during the forecast period.

Growing prevalence of the diseases in the US and presence of key market players in this region is expected to contribute to the regional growth during the forecast period. Moreover, the approval of drugs and development of new methods such as step cell therapy for the treatment of anterior uveitis is driving the market growth across the region.

Anterior Uveitis Treatment Market Region

Segments

The global anterior uveitis treatment market has been divided based on treatment types, distribution channels, and regions.

By Treatment Types

  • Corticosteroids
  • Cycloplegic Agents
  • Anti-TNF Agents
  • Immunosuppressants

By Distribution Channels

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Regions

  • North America
  • Europe
  • Latin America
  • Asia Pacific
  • Middle East & Africa

By Key Players

  • Santen Pharmaceutical Co. Ltd.
  • AbbVie Inc.
  • Novartis AG
  • Eyegate Pharmaceuticals Inc.
  • Aldeyra Therapeutics Inc.
  • Aciont Inc.
  • Clearside Biomedical Inc.
  • Sirion Therapeutics Inc.
  • Lux Biosciences Inc.
  • Bausch & Lomb Incorporated
  • UCB Biopharma S.P.R.L.
  • EyePoint Pharmaceuticals Inc.
  • Alimera Sciences Inc.
  • Regeneron Pharmaceuticals

Competitive Landscape

Key players in the global anterior uveitis treatment market includes Santen Pharmaceutical Co., Ltd., AbbVie Inc., Novartis AG, Eyegate Pharmaceuticals, Inc., Aldeyra Therapeutics, Inc., Aciont Inc., Clearside Biomedical, Inc., Sirion Therapeutics, Inc., Lux Biosciences, Inc., Bausch & Lomb Incorporated, UCB Biopharma S.P.R.L., EyePoint Pharmaceuticals, Inc., Alimera Sciences Inc., and Regeneron Pharmaceuticals.

Collaborations, mergers, acquisitions, agreements, and partnerships are strategies adopted by these players to strengthen their geographical presence.

Anterior Uveitis Treatment Market Key Players

Table Of Content

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Anterior Uveitis Treatment Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Anterior Uveitis Treatment Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Anterior Uveitis Treatment Market - Supply Chain
  4.5. Global Anterior Uveitis Treatment Market Forecast
     4.5.1. Anterior Uveitis Treatment Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Anterior Uveitis Treatment Market Size (000’ Units) and Y-o-Y Growth
     4.5.3. Anterior Uveitis Treatment Market Absolute $ Opportunity
5. Global Anterior Uveitis Treatment Market Analysis and Forecast by Types
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Types
     5.2.2. Y-o-Y Growth Projections by Types
  5.3. Anterior Uveitis Treatment Market Size and Volume Forecast by Types
     5.3.1. Corticosteroids
     5.3.2. Cycloplegic Agents
     5.3.3. Anti-TNF Agents
     5.3.4. Immunosuppressants
  5.4. Absolute $ Opportunity Assessment by Types
  5.5. Market Attractiveness/Growth Potential Analysis by Types
6. Global Anterior Uveitis Treatment Market Analysis and Forecast by Region
  6.1. Market Trends
  6.2. Introduction
     6.2.1. Basis Point Share (BPS) Analysis by Region
     6.2.2. Y-o-Y Growth Projections by Region
  6.3. Anterior Uveitis Treatment Market Size and Volume Forecast by Region
     6.3.1. North America
     6.3.2. Latin America
     6.3.3. Europe
     6.3.4. Asia Pacific
     6.3.5. Middle East and Africa (MEA)
  6.4. Absolute $ Opportunity Assessment by Region
  6.5. Market Attractiveness/Growth Potential Analysis by Region
  6.6. Global Anterior Uveitis Treatment Demand Share Forecast, 2019-2026
7. North America Anterior Uveitis Treatment Market Analysis and Forecast
  7.1. Introduction
     7.1.1. Basis Point Share (BPS) Analysis by Country
     7.1.2. Y-o-Y Growth Projections by Country
  7.2. North America Anterior Uveitis Treatment Market Size and Volume Forecast by Country
     7.2.1. U.S.
     7.2.2. Canada
  7.3. Absolute $ Opportunity Assessment by Country
  7.4. North America Anterior Uveitis Treatment Market Size and Volume Forecast by Types
     7.4.1. Corticosteroids
     7.4.2. Cycloplegic Agents
     7.4.3. Anti-TNF Agents
     7.4.4. Immunosuppressants
  7.5. Basis Point Share (BPS) Analysis by Types
  7.6. Y-o-Y Growth Projections by Types
  7.7. Market Attractiveness/Growth Potential Analysis
     7.7.1. By Country
     7.7.2. By Product Type
     7.7.3. By Application
  7.8. North America Anterior Uveitis Treatment Demand Share Forecast, 2019-2026
8. Latin America Anterior Uveitis Treatment Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
     8.1.3. Latin America Average Pricing Analysis
  8.2. Latin America Anterior Uveitis Treatment Market Size and Volume Forecast by Country
      8.2.1. Brazil
      8.2.2. Mexico
      8.2.3. Rest of Latin America
   8.3. Absolute $ Opportunity Assessment by Country
  8.4. Latin America Anterior Uveitis Treatment Market Size and Volume Forecast by Types
     8.4.1. Corticosteroids
     8.4.2. Cycloplegic Agents
     8.4.3. Anti-TNF Agents
     8.4.4. Immunosuppressants
  8.5. Basis Point Share (BPS) Analysis by Types
  8.6. Y-o-Y Growth Projections by Types
  8.7. Market Attractiveness/Growth Potential Analysis
     8.7.1. By Country
     8.7.2. By Product Type
     8.7.3. By Application
  8.8. Latin America Anterior Uveitis Treatment Demand Share Forecast, 2019-2026
9. Europe Anterior Uveitis Treatment Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Europe Average Pricing Analysis
  9.2. Europe Anterior Uveitis Treatment Market Size and Volume Forecast by Country
     9.2.1. Germany
     9.2.2. France
     9.2.3. Italy
     9.2.4. U.K.
     9.2.5. Spain
     9.2.6. Russia
     9.2.7. Rest of Europe
  9.3. Absolute $ Opportunity Assessment by Country
  9.4. Europe Anterior Uveitis Treatment Market Size and Volume Forecast by Types
     9.4.1. Corticosteroids
     9.4.2. Cycloplegic Agents
     9.4.3. Anti-TNF Agents
     9.4.4. Immunosuppressants
  9.5. Basis Point Share (BPS) Analysis by Types
  9.6. Y-o-Y Growth Projections by Types
  9.7. Market Attractiveness/Growth Potential Analysis
     9.7.1. By Country
     9.7.2. By Product Type
     9.7.3. By Application
  9.8. Europe Anterior Uveitis Treatment Demand Share Forecast, 2019-2026
10. Asia Pacific Anterior Uveitis Treatment Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Asia Pacific Average Pricing Analysis
  10.2. Asia Pacific Anterior Uveitis Treatment Market Size and Volume Forecast by Country
     10.2.1. China
     10.2.2. Japan
     10.2.3. South Korea
     10.2.4. India
     10.2.5. Australia
     10.2.6. Rest of Asia Pacific (APAC)
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Asia Pacific Anterior Uveitis Treatment Market Size and Volume Forecast by Types
     10.4.1. Corticosteroids
     10.4.2. Cycloplegic Agents
     10.4.3. Anti-TNF Agents
     10.4.4. Immunosuppressants
  10.5. Basis Point Share (BPS) Analysis by Types
  10.6. Y-o-Y Growth Projections by Types
  10.7. Market Attractiveness/Growth Potential Analysis
     10.7.1. By Country
     10.7.2. By Product Type
     10.7.3. By Application
  10.8. Asia Pacific Anterior Uveitis Treatment Demand Share Forecast, 2019-2026
11. Middle East & Africa Anterior Uveitis Treatment Market Analysis and Forecast
  11.1. Introduction
     11.1.1. Basis Point Share (BPS) Analysis by Country
     11.1.2. Y-o-Y Growth Projections by Country
     11.1.3. Middle East & Africa Average Pricing Analysis
  11.2. Middle East & Africa Anterior Uveitis Treatment Market Size and Volume Forecast by Country
     11.2.1. Saudi Arabia
     11.2.2. South Africa
     11.2.3. UAE
     11.2.4. Rest of Middle East & Africa (MEA)
  11.3. Absolute $ Opportunity Assessment by Country
  11.4. Middle East & Africa Anterior Uveitis Treatment Market Size and Volume Forecast by Types
     11.4.1. Corticosteroids
     11.4.2. Cycloplegic Agents
     11.4.3. Anti-TNF Agents
     11.4.4. Immunosuppressants
  11.5. Basis Point Share (BPS) Analysis by Types
  11.6. Y-o-Y Growth Projections by Types
  11.7. Market Attractiveness/Growth Potential Analysis
     11.7.1. By Country
     11.7.2. By Product Type
     11.7.3. By Application
  11.8. Middle East & Africa Anterior Uveitis Treatment Demand Share Forecast, 2019-2026
12. Competition Landscape
  12.1. Global Anterior Uveitis Treatment Market: Market Share Analysis
  12.2. Anterior Uveitis Treatment Distributors and Customers
  12.3. Anterior Uveitis Treatment Market: Competitive Dashboard
  12.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     12.4.1. Santen Pharmaceutical Co. Ltd.
     12.4.2. AbbVie Inc.
     12.4.3. Novartis AG
     12.4.4. Eyegate Pharmaceuticals Inc.
     12.4.5. Aldeyra Therapeutics Inc.
     12.4.6. Aciont Inc.
     12.4.7. Clearside Biomedical Inc.
     12.4.8. Sirion Therapeut

Methodology

Our Clients

Pfizer
Microsoft
Deloitte
Honda Motor Co. Ltd.
sinopec
Dassault Aviation
Nestle SA
General Electric